Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093001 · ClinicalTrials.gov registry record · Phase 4
Tricuspid Regurgitation Study
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 119
- Enrollment target
NCT01093001: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT01093001 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01093001, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 119 participants
- Enrollment target
Study Summary
The effect of cardiac pacing leads on tricuspid regurgitation is unclear. This study will determine whether using a smaller diameter leads and an alternate position in the ventricle, the proximal septum, will reduce tricuspid regurgitation than larger leads placed in the apex.
Interventions
- OTHER Echo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2010-05 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093001
The ClinicalTrials.gov registry entry for NCT01093001 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Echo is the first listed.
NCT01093001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093001 about?
NCT01093001 is a clinical study titled "Tricuspid Regurgitation Study". The effect of cardiac pacing leads on tricuspid regurgitation is unclear. This study will determine whether using a smaller diameter leads and an alternate position in the ventricle, the proximal septum, will reduce tricuspid regurgitation than larger leads placed in the apex.
What is the current status of trial NCT01093001?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 119 participants. The study started on 2010-05. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01093001?
The interventions under investigation include: Echo (OTHER).
Who is sponsoring clinical trial NCT01093001?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.